Report Sections

See All Reports

  • HP:0100598: Pulmonary edema
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0100598: Pulmonary edema

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (10)


    Name (Synonyms) Correlation
    drug3126 Pemziviptadil (PB1046) Wiki 0.58
    drug3448 Pulmonary Vascular Permeability Index Wiki 0.58
    drug1599 Extravascular Lung Water Index Wiki 0.58
    Name (Synonyms) Correlation
    drug728 C2Rx Wiki 0.58
    drug2393 Low Dose (10 mg) Control Wiki 0.58
    drug319 Angiotensin-(1-7) Wiki 0.41
    drug364 Apremilast Wiki 0.33
    drug4104 Standard of Care (SOC) Wiki 0.26
    drug4112 Standard of care Wiki 0.11
    drug3195 Placebo Wiki 0.05

    Correlated MeSH Terms (10)


    Name (Synonyms) Correlation
    D011654 Pulmonary Edema NIH 1.00
    D000075902 Clinical Deterioration NIH 0.41
    D011665 Pulmonary Valve Insufficiency NIH 0.19
    Name (Synonyms) Correlation
    D006333 Heart Failure NIH 0.14
    D007249 Inflammation NIH 0.10
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.09
    D055371 Acute Lung Injury NIH 0.09
    D012128 Respiratory Distress Syndrome, Adult NIH 0.08
    D013577 Syndrome NIH 0.05
    D011014 Pneumonia NIH 0.03

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0010444 Pulmonary insufficiency HPO 0.19
    HP:0001635 Congestive heart failure HPO 0.14
    HP:0002090 Pneumonia HPO 0.03

    Clinical Trials

    Navigate: Correlations   HPO

    There are 3 clinical trials


    1 A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)

    This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.

    NCT04433546
    Conditions
    1. Acute Respiratory Distress Syndrome
    2. Coronavirus
    3. Hypoxic Respiratory Failure
    4. Hypoxemic Respiratory Failure
    5. Respiratory Complication
    6. Respiratory Insufficiency
    7. Cardiac Dysfunction
    8. Pneumonia
    9. Pulmonary Edema
    10. Pulmonary Inflammation
    11. Respiratory Failure
    12. Cytokine Storm
    13. COVID 19
    14. SARS-CoV-2
    15. Cardiac Event
    16. Cardiac Complication
    17. Cardiac Failure
    18. Cardiac Infarct
    Interventions
    1. Drug: Pemziviptadil (PB1046)
    2. Drug: Low Dose (10 mg) Control
    MeSH:Pneumonia Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Respiratory Insufficiency Acute Lung Injury Pulmonary Edema Pulmonary Valve Insufficiency Heart Failure Syndrome Inflammation Clinical Deterioration
    HPO:Abnormal left ventricular function Congestive heart failure Pneumonia Pulmonary edema Pulmonary insufficiency Right ventricular failure

    Primary Outcomes

    Measure: Time to clinical recovery from initiation of pemziviptadil (PB1046)

    Time: 28 days

    Secondary Outcomes

    Measure: Time to clinical recovery (being well enough for hospital discharge or returning to normal baseline activity level prior to discharge)

    Time: 28 days

    Measure: Time to hospital discharge

    Time: Any time point between injection initiation and Day 28

    Measure: All-cause mortality

    Time: 28 days

    Description: Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapy

    Measure: Reduction in hospital resource utilization defined as a composite of: total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy

    Time: 28 days

    Measure: Time to clinical improvement as defined by reduction of at least 2 points on an 8-category ordinal scale of clinical improvement or discharge from hospital, whichever comes first.

    Time: Any time point between injection initiation and Day 28

    Measure: Change from baseline in cardiac marker troponin I (TrI)

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change from baseline in cardiac marker NT-proBNP/BNP

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change from baseline in TNF alpha

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change from baseline in IL-1

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change from baseline in IL-6

    Time: Any time point between injection initiation and Day 35+7

    Measure: Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by clinical adverse events (AEs) and their relationship to pemziviptadil (PB1046).

    Time: Any time point between injection initiation and Day 35+7

    Measure: Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by vital signs and their relationship to pemziviptadil (PB1046)

    Time: Any time point between injection initiation and Day 35+7

    Measure: Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by laboratory results and their relationship to pemziviptadil (PB1046)

    Time: Any time point between injection initiation and Day 35+7

    Measure: Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by electrocardiogram (ECG) abnormalities and their relationship to pemziviptadil (PB1046)

    Time: Any time point between injection initiation and Day 35+7

    Measure: Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by incidence of anti-drug antibodies and their relationship to pemziviptadil (PB1046)

    Time: Any time point between injection initiation and Day 35+7

    Other Outcomes

    Measure: Impact on invasive hemodynamic parameters as measured by pulmonary artery pressure if patients require right-heart catherization

    Time: Any time point between injection initiation and Day 35+7

    Measure: Impact on invasive hemodynamic parameters as measured by cardiac output if patients require right-heart catherization

    Time: Any time point between injection initiation and Day 35+7

    Measure: Incidence of multi-system organ failure (MSOF)

    Time: Any time point between injection initiation and Day 35+7

    Measure: Number of multi-system organ failure (MSOF) free days

    Time: Any time point between injection initiation and Day 35+7

    Measure: Number of subjects requiring extracorporeal membrane oxygenation (ECMO)

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change in circulating ferritin

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change in circulating D-dimer

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change in liver function

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change in other blood chemistry

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change in hematology

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change in inflammatory markers

    Time: Any time point between injection initiation and Day 35+7

    Measure: Change in coagulation markers

    Time: Any time point between injection initiation and Day 35+7

    Measure: Percent of clinical failure

    Time: Any time point between injection initiation and Day 35+7
    2 Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and "Typical"ARDS Patients

    Covid-19 also primarily affects endothelium that line up the alveoli. The resulting hypoxemia may differ from "typical" Acute Respiratory Distress Syndrome (ARDS) due to maldistribution of perfusion related to the ventilation. Thus, pathophysiology of Covid-19 ARDS is different, which requires different interventions than typical ARDS. The investigators will assess whether extravascular lung water index and permeability of the alveolar capillary differs from typical ARDS with transpulmonary thermodilution (TPTD) technique. Extravascular Lung Water Index (EVLWI) and Pulmonary Vascular Permeability Index (PVPI) will be compared.

    NCT04508933
    Conditions
    1. Respiratory Distress Syndrome, Adult
    2. Ventilation Perfusion Mismatch
    3. Pulmonary Edema
    4. Covid19
    Interventions
    1. Device: Extravascular Lung Water Index
    2. Device: Pulmonary Vascular Permeability Index
    MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Pulmonary Edema Acute Lung Injury
    HPO:Pulmonary edema

    Primary Outcomes

    Description: The amount of fluid accumulated in the lung measured by transpulmonary thermodilution (ml/kg)

    Measure: Extravascular Lung Water Index

    Time: 1 day

    Description: Integrity of the alveolocapillary barrier measured by transpulmonary thermodilution

    Measure: Pulmonary vascular permeability index

    Time: 1 day
    3 A Randomized Clinical Trial of CLR2.0 Hemofiltration Treatment (C2Rx) in Severe or Critically Ill Adults With COVID-19 Infection

    The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19 infections .

    NCT04537975
    Conditions
    1. Continuous Renal Replacement The
    2. Continuous Renal Replacement Therapy
    3. Pulmonary Edema
    4. COVID-19
    Interventions
    1. Device: C2Rx
    2. Other: Standard of Care (SOC)
    MeSH:Pulmonary Edema
    HPO:Pulmonary edema

    Primary Outcomes

    Description: Change in patient Arterial Oxygen Partial Pressure (PaO2)/Fractional Inspired Oxygen (FiO2) Ratio

    Measure: Pulmonary Oxygenation Function

    Time: Up to 72 hours

    Secondary Outcomes

    Description: Change in patient oxygenation

    Measure: Pulmonary Compliance of Respiratory System (CRS)

    Time: Up to 96 hours

    Description: Change in the total number of patients that survived

    Measure: Survival

    Time: 30 days and 60 days

    Description: Change in Hospital Utilization of ventilators (days)

    Measure: Hospital Costs 1

    Time: Out to 60 days

    Description: Change in score based on the calculation of the following medications used: dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 x adrenaline dose (µg/kg/min) + 100 x noradrenaline dose (µg/kg/min) + 10 x milrinone dose (µg/kg/min) + 10.000 x vasopressin dose (U/kg/min)

    Measure: Cardiovascular Vasoactive-Inotropic Score (VIS)

    Time: Up to 96 hours

    Description: Change in Hospital Utilization of vasopressor medication (days without use)

    Measure: Hospital Costs 2

    Time: Out to 60 days

    Description: Change in Hospital Utilization of Intensive Care Unit (ICU) Hospital free days

    Measure: Hospital Costs 3

    Time: Out to 60 days

    Description: Change in Hospital Utilization of Renal Replacement Therapy (days on therapy)

    Measure: Hospital Costs 4

    Time: Out to 60 days

    Description: Change in Hospital Utilization (days hospitalized)

    Measure: Hospital Costs 5

    Time: Out to 60 days

    Other Outcomes

    Description: Changes in inflammatory mediators detected by Immunoassay of Multianalyte Panel - MAP Laboratory Panel of 253 analytes.

    Measure: Inflammatory mediators in blood

    Time: Out to 14 hours

    Description: Change in cytokine levels obtained from plasma and blood collected prior to and after filter. Analyte concentrations in ultrafiltrate and plasma, expressed in the same concentration units, will be aggregated as a ratio of ultrafiltrate concentration to plasma concentration to yield a unitless Sieving Coefficient (SC). SC is an index of membrane function.

    Measure: Cytokine Sieving Effects

    Time: Out to 8 hours

    Description: Change in blood Ferritin (mg/mL)

    Measure: Specific Blood Indicators 1

    Time: Out to 14 hours

    Description: Change in blood Interleukin-6 (pg/mL)

    Measure: Specific Blood Indicators 2

    Time: Out to 14 hours

    Description: Change in blood C-reactive protein (CRP) (mg/L)

    Measure: Specific Blood Indicators 3

    Time: Out to 14 hours

    Description: Change in blood Lactate Dehydrogenase (LDH) (U/L)

    Measure: Specific Blood Indicators 4

    Time: Out to 14 hours

    Description: Change in blood D-dimer (mcg/L*FEU2)

    Measure: Specific Blood Indicators 5

    Time: Out to 14 hours

    Description: Change in blood White Blood Cell (WBC) count (%)

    Measure: Specific Blood Indicators 6

    Time: Out to 14 hours

    Description: Change in blood Neutrophil count (%)

    Measure: Specific Blood Indicators 7

    Time: Out to 14 hours

    Description: Change in blood lymphocyte count (%).

    Measure: Specific Blood Indicators 8

    Time: Out to 14 hours

    Description: Change in the duration of days of diagnosed HAI/ Sepsis infections

    Measure: Hospital Acquired Infections (HAI) /Sepsis

    Time: 30 and 60 days

    Description: Duration without Respiratory Replacement Therapy (RRT), ventilator, and time to discharge

    Measure: Composite Recovery

    Time: Up to 30 days

    Description: Survival without Respiratory Replacement Therapy (RRT), ventilator, or time to Long Term Care (LTC)

    Measure: Composite Survival

    Time: 30 and 60 days

    Description: Survival with Respiratory Replacement Therapy (RRT), ventilator or in Long Term Care (LTC)

    Measure: Composite Non-Recovery

    Time: Up to 60 days

    HPO Nodes


    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook